HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Weighing Shortage Risk, FDA Clears Releasing Metabolic Formulas Made At Abbott’s Closed Plant

Executive Summary

With Michigan facility closed as cause of bacterial contamination is investigated, FDA announces “has no objection” to Abbott releasing specialty and metabolic formulas “to individuals needing urgent, life-sustaining supplies” on a case-by-case basis.

You may also be interested in...



Preliminary Remediation Begins On Restarting Formula Production At Abbott Nutrition Plant

Decree imposes steps Abbott must complete before it can begin preparing to restart production, including hiring independent consultant to determine whether facility is compliant with FDA manufacturing and labeling regulations.

US Lawmakers Want Answers From FDA On Infant Formula Shortage Following Abbott Recall

House Appropriations and Energy and Commerce subcommittees will ask about Abbott Nutrition’s recall of infant formula made at its Sturgis, MI, facility. “We are doing everything in our power to ensure there is adequate product available where and when they need it,” says FDA Commissioner Robert Califf.

Perrigo Boosts 2022 Guidance Shifting From Changing Organization To Delivering Results

“We said we would start growing this company ... and this is the year to do it,” says CERO Murray Kessler. With nearly 11% net sales growth for its Americas business leading nearly 10% overall Q1 growth, Perrigo raises full-year guidance for net sales growth to 8% to 9%, up earlier 7% to 8%.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS152469

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel